11.3 FDA SIUU Guidance & Promotional/Scientific Communication Boundaries

FDA SIUU Guidance & Promotional/Scientific Communication Boundaries

Check Current Implementation Status

The FDA webpage currently labels the January 2025 document as final guidance but also states that it is not for current implementation pending a decision by the Office of Management and Budget. That status matters. A publication professional should:

1. verify the current FDA webpage and document date;
2. involve regulatory, legal, and compliance specialists;
3. follow binding law and current company controls;
4. avoid presenting the guidance as a guaranteed safe harbor.

Guidance describes an agency's current thinking and generally does not create legally enforceable rights or obligations by itself. The surrounding statutory, regulatory, constitutional, and case-specific context remains important.

Scope of the SIUU Guidance

The 2025 guidance addresses certain firm-initiated communications to healthcare professionals about scientific information on unapproved uses of approved or cleared medical products. “Unapproved use” may include an unapproved indication, patient population, dose, route, or other use outside the approved labeling.

The guidance discusses source publications and certain firm-generated presentations of scientific information. It aims to help firms make communications that are truthful and non-misleading and that provide useful scientific context. It is not a license to promote an unapproved use, and compliance with a checklist does not immunize misleading conduct.

It also does not govern every publication activity. A peer-reviewed article developed by independent authors, a response to an unsolicited medical-information request, an investor communication, a congress exhibit, a promotional claim, and a scientific exchange program can raise different rules and facts.

Why the Older “Good Reprint Practices” Rule Is Obsolete

Do not teach the 2009 Good Reprint Practices guidance or the 2014 draft as the current FDA standard. The January 2025 final document expressly replaces them. Consequently, a quiz that asks candidates to apply a fixed eight-part “Good Reprint Practices safe harbor” is outdated.

Some familiar principles remain relevant—source quality, complete context, disclosure of unapproved status, balance, approved labeling, and separation from promotion—but they must be learned from the current document and current implementation status, not from an obsolete checklist.

Truthful and Non-Misleading Scientific Context

A scientifically responsible communication should allow an HCP to assess reliability and relevance. Relevant considerations include:

• the quality and design of the underlying study;
• whether the source is peer reviewed and scientifically sound;
• consistency with the broader evidence, including contrary or unfavorable information;
• whether conclusions exceed the design or data;
• disclosure that the discussed use is unapproved;
• the product's approved use and access to current approved labeling;
• material limitations, biases, uncertainty, and safety context;
• financial interests and the firm's involvement.

A statistically significant result can still mislead if the analysis was exploratory, the comparator inappropriate, important harms omitted, or the visual display exaggerates effect size.

Source Publication and Firm-Generated Material

Distributing an independent scientific publication and creating a firm-generated presentation are not the same act. A firm-generated summary, deck, email, or digital interface introduces additional choices about selection, emphasis, headlines, graphics, excerpts, and links. Those choices can change the overall impression.

Do not:

• cherry-pick favorable passages;
• use promotional slogans or product claims;
• obscure the unapproved nature of the use;
• omit material limitations or contrary evidence;
• crop figures in a way that changes meaning;
• present surrogate or subgroup findings as proven patient benefit;
• combine scientific material with promotional calls to action.

A complete article is not automatically non-promotional, and an accurate quotation does not cure a misleading overall presentation.

Separation and Context

The current guidance discusses separating SIUU communications from promotional communications. Evaluate physical and digital placement, timing, links, branding, surrounding messages, and the role of the personnel delivering the communication.

A department name is not dispositive. A Medical Affairs communication can be promotional in context, and scientific staff do not create immunity merely by delivering it. Conversely, the legal analysis should not be reduced to “commercial personnel may never see a publication.” Organizations need documented governance that preserves scientific integrity, allows required legal or compliance review, and prevents marketing control of scientific conclusions.

Unsolicited Requests

A genuine unsolicited request is initiated independently by the requester. Responses should be tailored, accurate, balanced, documented, and handled under current medical-information procedures. A representative must not prompt an HCP to ask an off-label question and then label the response unsolicited.

Do not assume the 2025 SIUU document replaces all policies for unsolicited requests. Determine which current FDA materials and organizational procedures govern the particular communication.

Investigational Products

For investigational drugs, 21 CFR 312.7 prohibits representing an investigational drug as safe or effective for the purpose for which it is under investigation, while explaining that the provision is not intended to restrict full scientific exchange. The existence of scientific exchange does not permit preapproval promotion.

Publications and congress presentations should accurately state investigational status, avoid conclusions beyond the evidence, and follow trial-registration, disclosure, embargo, conference, and applicable securities controls.

European Context

European rules are not simply “the FDA rule with an SmPC.” EU legislation and national implementation regulate advertising, including the prohibition on advertising unauthorized medicinal products and the requirement that advertising of authorized products conform to the Summary of Product Characteristics. EFPIA and national association codes add self-regulatory obligations.

Whether an activity is advertising or non-promotional scientific exchange is fact-specific and may differ by country. Medical-information responses, international congresses, pipeline data, press activity, and digital access require local review. Do not claim that all off-label exchange must use one channel in every European jurisdiction.

Applied Review Framework

Before distributing or presenting scientific information related to an unapproved use, ask: